Current Portfolio

 

ProductMarketerMarketerCreditRating(1)IndicationApproved/ In DevelopmentProductSales RankforMarketerProductTherapeuticRanking2014 SalesRating(2)RoyaltySeller
               
Approved
             
Atripla/Truvada/
Emtriva/Complera (3)
more info
NR
A+/A2
AA-/Aa3
HIV/AIDS #1 #1 $9,368 (3) Emory
               
Cimzia
more info
NR Rheumatoid Arthritis (RA), Crohn's #2 #3 $1,059 Nektar Therapeutics
               
Cubicin
more info
NR
NR
AA-/AA2
cSSSI, Bacteremia, Endocarditis #1 #2 $1,097 - -
               
Galvus/Eucreas
more info
NR Diabetes -- #2 $1,224 Astellas
               
Humira
more info
AA/A1 Rheumatoid Arthritis (RA), UC,
Crohn´s, PsA, AS, Psoriasis
#1 #1 / #2 $12,543 AstraZeneca
               
Imbruvica
more info
--
AAA/Aaa
Mantle Cell Lymphoma (MCL) -- -- $547 Quest Diagnostics
               
Januvia/Janumet
more info
AA-/Aa3 Diabetes #1 #1 $6,011 Astellas
               
Kalydeco
more info
  Cystic Fibrosis (CF)     -- Cystic Fibrosis Foundation
               
Letairis/Volibris
more info
NR PAH - - #2 $595 - -
               
Lexiscan
more info
NR Pharmacological Stress Agent for MPI #2 #1 $602 - -
               
Lyrica
more info
AA/A1 Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia #1 #1 $5,168 Northwestern University
               
Mircera
more info
AA-/A2 Chronic Kidney Disease (CKD) -- #2 $457 Nektar Therapeutics
               
Myozyme/Lumizyme
more info
A-/BBB+ Pompe Disease #2 #1 $720 - -
               
Nesina
more info
NR Diabetes -- #4 $405 Astellas
               
Neupogen/Neulasta
more info
A+/A3 Cancer, white blood cell stimulant #1 Sole $5,758 MSK
               
Onglyza/Kombiglyze
more info
A+/A2 Diabetes -- #3 $958 Astellas
               
Orkambi
more info
  Cystic Fibrosis (CF)     -- Cystic Fibrosis Foundation
               
Prezista
more info
AAA/Aaa HIV/AIDS - - - - $1,884 - -
               
Priligy
more info
The Menarini Group -- Male Sexual Dysfunction -- -- -- Forest Laboratories
Furiex Pharmaceuticals
               
Remicade
more info
AAA/Aaa
AA-/Aa3
Rheumatoid Arthritis (RA), UC, Crohn´s, PsA, AS, Psoriasis #1
#3
#2 / #1
#1
$8,807 NYU
               
Rituxan - US
more info
AA-/A2 B-cell Lymphoma, RA,
Multiple Sclerosis, Lupus
#1 #1 $3,470 XOMA
               
RotaTeq
more info
AA-/Aa3 Rotavirus Vaccine - - #1 $724 CHOP
               
Savella
more info
NR Fibromyalgia - - #3 $72 - -
               
Tecfidera
more info
A- Psoriasis, Multiple Sclerosis - - - - $2,909 - -
               
Thalomid
more info
NR/NR Multiple Myeloma #4 #2 $221 - -
               
TOBI
more info
AA-/- Anti-Infectives (cystic fibrosis) -- -- -- - -
               
Tradjenta
more info
-- Diabetes -- #5 $565 Astellas
               
Tysabri
more info
Biogen -- Relapsing forms of multiple sclerosis (MS) -- -- -- Perrigo
               
Viviant
more info
AA/A1 2nd gen. SERM: Osteoporosis Best in Class -- -- Ligand
               
Xtandi
more info
Medivation logo -- Metastatic castration-resistant prostate cancer (CRPC) -- -- -- UCLA
               
In Development
             
Conbriza/Aprela (4)
more info
AA/A1 2nd gen. SERM: Osteoporosis Best in Class - - -- Ligand
               
Vosaroxin
more info
  Acute Myeloid Leukemia (AML)     -- Sunesis
               
               
Total $64,002 
       
(1) S&P / Moody's
(2) Sales in $M in territories for which Royalty Pharma receives royalties.
(3) Aggregate end-user sales of all products; Royalty Pharma receives royalties on emtricitabine-related portion.
(4) Approved in select EU countries and Japan.

 

 


© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.